NEUP vs BIIB vs KO vs ACAD vs PRAX

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 4x versus The Coca-Cola Company at 26. 1x. On forward P/E, Biogen Inc. is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

3%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: KO returned +115. 0% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Praxis Precision Medicines, Inc. 's 1. 49β — meaning PRAX is approximately -739% more volatile than KO relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 5x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 42. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 106. 9% to $584. 00.

In this comparison, KO (2.

6% yield) pays a dividend. NEUP, BIIB, ACAD, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, PRAX: -32. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEUP (Healthcare) and BIIB (Healthcare) and KO (Consumer Defensive) and ACAD (Healthcare) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEUP is a small-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock; ACAD is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock. KO pays a dividend while NEUP, BIIB, ACAD, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.